Kexing Biopharm Balance Sheet Health
Financial Health criteria checks 2/6
Kexing Biopharm has a total shareholder equity of CN¥1.6B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 69.9%. Its total assets and total liabilities are CN¥3.0B and CN¥1.4B respectively.
Key information
69.9%
Debt to equity ratio
CN¥1.13b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥468.21m |
| Equity | CN¥1.62b |
| Total liabilities | CN¥1.38b |
| Total assets | CN¥3.00b |
Recent financial health updates
No updates
Recent updates
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise
Oct 08
Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
May 21Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%
Mar 08Financial Position Analysis
Short Term Liabilities: 688136's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥762.9M).
Long Term Liabilities: 688136's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥616.9M).
Debt to Equity History and Analysis
Debt Level: 688136's net debt to equity ratio (41%) is considered high.
Reducing Debt: 688136's debt to equity ratio has increased from 31.5% to 69.9% over the past 5 years.
Debt Coverage: 688136's debt is not well covered by operating cash flow (3.6%).
Interest Coverage: Insufficient data to determine if 688136's interest payments on its debt are well covered by EBIT.